<DOC>
	<DOCNO>NCT00487539</DOCNO>
	<brief_summary>The purpose study assess effect ( good bad ) golimumab ( CNTO 148 ) therapy participant ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Golimumab ( CNTO 148 ) Participants With Moderately Severely Active Ulcerative Colitis</brief_title>
	<detailed_description>This multi-center ( conducted one center ) , randomize ( study medication assign chance ) , double-blind ( neither physician participant know study medication ) , placebo-controlled ( inactive substance compare drug test whether drug real effect clinical trial ) , parallel-group ( medical research study compare response 2 group participant receive different intervention ) study evaluate safety efficacy golimumab participant moderately severely active UC . There 2 part study . Part 1 `` Phase 2 dose-ranging '' portion study . Participants enrol Part 1 , receive subcutaneous ( skin way needle ) injection placebo , golimumab 100 milligram ( mg ) , 200 mg , 400 mg Week 0 , follow subcutaneous injection placebo , golimumab 50 mg , 100 mg , 200 mg respectively Week 2 . Part 2 `` Phase 3 dose-confirming '' portion study newly enrol participant receive dos study Part 1 , dos Part 2 select . At time final dos select , newly enrol participant receive 1 select dos match placebo . At Week 6 , participant ask participate additional 1-year maintenance study . Participants enter 1-year golimumab maintenance study evaluate safety 16 week last administration study agent . The duration study 6 week participant enter 1-year golimumab maintenance study 16 week last administration study agent participant enter 1-year golimumab maintenance study . Efficacy participant primarily evaluate clinical response Week 6 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants diagnose moderately severely active ulcerative colitis ( UC ) define Mayo score 6 12 inclusive Baseline ( Week 0 ) , include endoscopic ( examination internal part body light tube ; look part body light tube ) subscore great equal 2 Participants must biopsy result ( collected screening endoscopy ( procedure obtain within last year ) consistent diagnosis UC Participants either currently receive treatment , history failure respond , tolerate , least 1 follow therapy : oral 5aminosalicylate , oral corticosteroid , 6mercaptopurine azathioprine Participants current dependency history corticosteroid dependency ( i.e. , inability successfully taper corticosteroid without return symptom UC ) Not diagnosis active tuberculosis Participants negative stool test enteric ( way intestine ) pathogens Participants prior exposure biologic antitumor necrosis factor ( TNF ) agents Participants severe extensive UC likely require colectomy ( surgery remove part colon ) within 12 week study entry Participants UC limit rectum le 20 centimeter colon Presence stoma ( artificial permanent open especially abdominal wall make surgical procedure ) presence fistula Participants history extensive colonic resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Colitis , Ulcerative</keyword>
	<keyword>Golimumab</keyword>
	<keyword>CNTO 148</keyword>
</DOC>